When a biological drug patent expires, alternative biosimilar products
are developed. The development of biosimilar products is complicated and
involves numerous considerations and steps. The assessment of
biosimilarity and interchangeability is also complicated and difficult. Biosimilar Drug Product Development
presents current issues for the development of biosimilars and gives
detailed reviews of its various stages and contributing factors as well
as relevant regulatory pathways and pre- and post-approval issues.
Table of Contents
Analytical characterization. Immunogenicity. Animal studies.
Clinical development. Manufacturing, process control. Extrapolation of
indications. Interchangeability, substitution. Pharmacovigilance.
Statistical issues. Regulatory issues.